926,379 Shares in Boston Scientific Corporation $BSX Purchased by PFA Pension Forsikringsaktieselskab

Key Points

• PFA Pension bought a new position of 926,379 shares in Boston Scientific worth about $88.94 million, representing roughly 0.06% ownership amid overall institutional ownership of 89.07%.
• Boston Scientific slightly beat Q1 expectations with $0.80 EPS vs $0.79 and revenue of $5.20 billion (up 11.6% YoY), and issued Q2 guidance of 0.820–0.840 EPS and FY2026 guidance of 3.340–3.410 EPS (consensus ~3.38).
• Near-term headwinds include analyst price‑target cuts and mounting securities‑class‑action notices, and the company’s CEO sold 160,901 shares (~$15.0M), trimming his stake by 10.23%, which may add to investor concern.

PFA Pension Forsikringsaktieselskab bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 926,379 shares of the medical equipment provider's stock, valued at approximately $88,942,000. PFA Pension Forsikringsaktieselskab owned approximately 0.06% of Boston Scientific as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new stake in Boston Scientific during the second quarter valued at approximately $26,000. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new stake in Boston Scientific during the third quarter valued at approximately $25,000. United Community Bank boosted its holdings in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares in the last quarter. Finally, Colonial Trust Co SC boosted its holdings in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Down 1.7%

Shares of BSX opened at $56.64 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The business's 50 day simple moving average is $67.06 and its 200-day simple moving average is $84.72. Boston Scientific Corporation has a one year low of $56.05 and a one year high of $109.50. The company has a market capitalization of $84.18 billion, a P/E ratio of 23.70, a PEG ratio of 1.06 and a beta of 0.78.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific's revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Institutional interest: hedge fund Lone Pine (Stephen Mandel) recently opened a new position in BSX, signaling some large investors view recent weakness as a buying opportunity. Stephen Mandel Opens New Position
• Positive Sentiment: Analyst conviction persists in places: media pieces note that the average brokerage recommendation still favors adding BSX — analysts continue to highlight long‑term fundamentals despite recent headwinds. Wall Street Analysts Think Boston Scientific Is a Good Investment
• Neutral Sentiment: Investor attention and commentary: several outlets (Zacks, MSN, Yahoo) are amplifying debate about BSX’s outlook — this increases short‑term volatility but is informational rather than a direct catalyst. Zacks: Attracting Investor Attention
• Negative Sentiment: Mounting securities‑class‑action notices and lead‑plaintiff deadlines (May 4) from multiple law firms are creating legal risk and headline pressure; numerous firms are soliciting plaintiffs and investigating potential misstatements about market growth/competition. This is likely a near‑term overhang. PR Newswire: Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi Reminder
• Negative Sentiment: Analyst downgrades and price‑target cuts: several firms have trimmed targets (Argus cut its PT to $95; other outlets report an ~11% PT reduction to ~$90 and Daiwa moved BSX from strong‑buy to hold). Those revisions reflect the company’s recent guidance/earnings and rising competitive pressures and are weighing on sentiment. Argus Price Target Cut Price Target Reduced

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BSX shares. Evercore decreased their price objective on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. Wall Street Zen downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Weiss Ratings downgraded Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, February 4th. BTIG Research decreased their price objective on Boston Scientific from $90.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday, April 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.